Polysaccharide and conjugate vaccines to Streptococcus pneumoniae generate distinct humoral responses
- 3 August 2022
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (656) , eabm4065
Abstract
Streptococcus pneumoniae is a major cause of community-acquired pneumonia, bacteremia, and meningitis in older adults worldwide. Two pneumococcal vaccines containing S. pneumoniae capsular polysaccharides are in current use: the polysaccharide vaccine PPSV23 and the glycoconjugate vaccine PCV13. In clinical trials, both vaccines elicit similar opsonophagocytic killing activity. In contrast to polysaccharide vaccines, conjugate vaccines have shown consistent efficacy against nasopharyngeal carriage and noninvasive pneumonia overall and for some prevalent individual serotypes. Given these different clinical profiles, it is crucial to understand the differential immunological responses induced by these two vaccines. Here, we used a high-throughput systems serology approach to profile the biophysical and functional features of serum antibodies induced by PCV13 and PPSV23 at 1 month and 1 year. In comparison with PPSV23, PCV13 induced higher titers across antibody isotypes; more durable antibody responses across immunoglobulin G (IgG), IgA, and IgM isotypes; and increased antigenic breadth. Although titers measured in opsonophagocytic activity (OPA) assays were similar between the two groups, confirming what was observed in clinical studies, serum samples from PCV13 vaccinees could induce additional non-OPA antibody-dependent functions, including monocyte phagocytosis and natural killer cell activation. In a multivariate modeling approach, distinct humoral profiles were demonstrated in each arm. Together, these results demonstrate that the glycoconjugate PCV13 vaccine induces an antigenically broader, more durable, polyfunctional antibody response. These findings may help explain the increased protection against S. pneumoniae colonization and noninvasive pneumonia and the longer duration of protection against invasive pneumococcal disease, mediated by PCV13.Keywords
This publication has 54 references indexed in Scilit:
- 13-valent Pneumococcal Conjugate Vaccine Given With Meningococcal C–Tetanus Toxoid Conjugate and Other Routine Pediatric VaccinationsThe Pediatric Infectious Disease Journal, 2012
- A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samplesJournal of Immunological Methods, 2011
- Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and ToddlersPediatrics, 2010
- How Bacterial Carbohydrates Influence the Adaptive Immune SystemAnnual Review of Immunology, 2010
- Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in miceJournal of Clinical Investigation, 2009
- Interleukin-17A Mediates Acquired Immunity to Pneumococcal ColonizationPLOS Pathogens, 2008
- Recent Primary Toxoplasma Infection Indicated by a Low Avidity of Specific IgGThe Journal of Infectious Diseases, 1989
- First and second dose antibody responses to pneumococcal polysaccharide vaccine in infantsThe Pediatric Infectious Disease Journal, 1986
- Antibody Response to Pneumococcal Vaccination in Children Younger than Five Years of AgeThe Journal of Infectious Diseases, 1983
- The serum igg subclass levels in healthy infants of 13–62 weeks of ageClinica Chimica Acta, 1980